Non-Small Cell Lung Cancer Clinical Trials
A listing of Non-Small Cell Lung Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Found 16 clinical trials
Intratumoral Gene Mediated Cytotoxic Immunotherapy (GMCI) For Resectable Non-Small Cell Lung Cancer
We will also assess time to progression and overall survival. The study is focusing on patients presenting with resectable NSCLC (4 cm) who are considered to be good surgical candidates, but at high risk for recurrence. The primary tumor must be accessible for vector delivery at the time of standard-of-care …
- 0 views
- 19 Feb, 2024
- 1 location
UPCC 21520: The LIMIT KRAS Mutant NSCLC Trial: Lysosome Inhibition to Enhance MAPK Inhibition Targeting KRAS Mutant NSCLC: A Phase 2 Open Label Trial of Binimetinib and Hydroxychloroquine in Patients with Advanced KRAS Mutant Non-Small Cell Lung Cancer
This study will evaluate using hydroxychloroquine (HCQ) along with binimetinib as an effective method for treating cancer. All patients will receive binimetinib at a standard dose approved for other cancers. The dose of HCQ will also be fixed based on ongoing phase I studies. Eligible subjects will have lung cancer …
- 0 views
- 19 Feb, 2024
- 1 location
UPCC 09517: Phase II study of Pembrolizumab and Itacitinib (INCB039110) for First Line Treatment of Metastatic Non-Small Cell Lung Cancer Expressing PD-L1
The main purpose of this study is to examine the efficacy of adding itacitinib (also known as INCB039110) to pembrolizumab in patients with previously untreated metastatic non-small cell lung cancer.
- 0 views
- 19 Feb, 2024
- 1 location
UPCC 15518 / ANAM-17-21: A Phase 3 Randomized Double-Blind Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
The main purpose of this study is to learn more about how well the experimental drug, anamorelin hydrochloride (HCl), works to prevent weight loss and anorexia in patients with advanced Non-Small Cell Lung Cancer.
- 0 views
- 19 Feb, 2024
- 1 location
UPCC 16520: A Phase Ib-II Trial of Tocilizumab and Atezolizumab in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy
This is an investigator-initiated, open label phase Ib study examining 2nd line atezolizumab and tocilizumab in a cohort of recurrent/metastatic non-small cell lung cancer patients who have received prior immune checkpoint inhibitor therapy with or without other forms of therapy (i.e. chemotherapy, radiation).
- 0 views
- 19 Feb, 2024
- 1 location
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
The purpose of this study is to find if adding the study drug, nivolumab (also known as OPVIDO), will limit lung cancer from growing back in patients with early stage non-small cell lung cancer. Nivolumab is a drug that may turn on the body's immune system to attack any cancer …
- 0 views
- 19 Feb, 2024
- 1 location
A Phase 1 Study of the Highly-selective RET
This is a phase 1 study with Highly-selective RET inhibiter, Blu-667, in patients with Thyroid Cancer, Non-Small cell lung cancer and other advanced solid tumors. The study will be conducted at multiple centers in the United States and Europe. the purpose of this trial is to determine the maximum tolerated …
- 0 views
- 19 Feb, 2024
- 1 location
Substudy: Understanding COVID-19 vaccine responses in the setting of immunotherapy
Anti-PD-1 antibody infusion is now increasingly being tested for other cancers as well, with relatively recent FDA-approval for use in metastatic non-small cell lung cancer, renal cell carcinoma, and metastatic or recurrent head and neck squamous cell carcinoma. This study is designed to better understand antibody responses in the setting …
- 0 views
- 19 Feb, 2024
- 1 location
A Phase 1/2 Study of Oral LOXO-292 in Patients
LOXO-292 is a highly potent and specific inhibitor of the RET RTK, with minimal inhibition of other kinase and non-kinase targets, and therefore may be of benefit to patients with tumors (such as NSCLC, MTC, PTC, and colon or breast carcinomas) that harbor RET alterations and/or depend on RET activation. …
- 0 views
- 19 Feb, 2024
- 1 location
- 1
- 2